药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02617 药捷安康-B

已收盘 07-22 16:08:03

10.900

+0.240

+2.25%

最高11.560	最低10.610	成交量1,011万
今开10.840	昨收10.660	日振幅8.91%
总市值44.47亿	流通市值34.12亿	总股本4.08亿
成交额1.12亿	换手率3.23%	流通股本3.13亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"药捷安康-B","latestPrice":10.9,"timestamp":1784707683007,"preClose":10.66,"halted":0,"volume":10106700,"delay":0,"changeRate":0.02251407129455912,"floatShares":313000000,"shares":408000000,"eps":-0.76,"marketStatus":"已收盘","change":0.24,"latestTime":"07-22 16:08:03","open":10.84,"high":11.56,"low":10.61,"amount":112244743,"amplitude":0.089118,"askPrice":10.91,"askSize":7500,"bidPrice":10.9,"bidSize":97500,"shortable":3,"etf":0,"ttmEps":-0.803,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784770200000},"marketStatusCode":5,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":10.66,"openAndCloseTimeList":[[1784683800000,1784692800000],[1784696400000,1784707200000]],"volumeRatio":0.897365,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617","defaultTab":"news","newsList":[{"id":"1131903847","title":"药捷安康-B：7月21日回购11.1万股，涉资约113.98万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1131903847","media":"公告速递","labels":[],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131903847?lang=zh_cn&edition=full","pubTime":"2026-07-21 20:21","pubTimestamp":1784636494,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年7月21日发布公告，披露当日于香港联交所场内回购H股111,000股，占公司现有已发行股份约0.036%。回购价格介乎每股港币9.92元至10.70元，总耗资约港币113.98万元。该回购依据公司于2026年6月18日通过的购回授权进行，可回购股份总数为31,268,767股，截至目前合计已回购291,000股，约占该授权总数的0.093%。公司确认，本次股份回购已获董事会正式授权，并遵守了相关上市规则及适用法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B：7月21日回购11.1万股，涉资约113.98万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653773072","title":"药捷安康-B(02617)7月21日斥资113.98万港元回购11.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653773072","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653773072?lang=zh_cn&edition=full","pubTime":"2026-07-21 20:17","pubTimestamp":1784636270,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)发布公告，于2026年7月21日斥资113.98万港元回购11.1万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172572961","title":"药捷安康-B：7月20日回购11.2万股，耗资约112.18万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172572961","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172572961?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:30","pubTimestamp":1784543456,"startTime":"0","endTime":"0","summary":"7月20日，药捷安康(南京)科技股份有限公司发布公告，披露于当日在香港联交所场内回购112,000股H股，占本次交易前已发行股份总数的约0.036%。回购价格介于每股港元9.83至10.09元之间，总耗资约112.18万港元。本次回购完成后，公司已发行股份数量为312,507,673股，库藏股数增至180,000股。公司表示，该次回购基于2026年6月18日获股东大会通过的回购授权进行，剩余可回购股份数量为31,268,767股。公司确认，本次回购已严格遵守香港联交所证券上市规则及其他相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B：7月20日回购11.2万股，耗资约112.18万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652129219","title":"药捷安康-B(02617)7月20日斥资112.18万港元回购11.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652129219","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652129219?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:28","pubTimestamp":1784543298,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)发布公告，于2026年7月20日，该公司斥资112.18万港元回购11.2万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469858.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652285044","title":"药捷安康-B(02617.HK)7月17日斥资约65.27万港元回购6.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652285044","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652285044?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:36","pubTimestamp":1784295397,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164251903","title":"药捷安康-B回购68,000股股份，总额约65.27万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164251903","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164251903?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:35","pubTimestamp":1784295357,"startTime":"0","endTime":"0","summary":"药捷安康-B（02617）于2026年7月17日发布公告，披露已于当日在香港联交所场内回购合计68,000股H股，占回购前已发行股本约0.022%。本次回购价格介于每股9.55港元至9.62港元，总金额约65.27万港元。\n本次回购完成后，公司已发行股本由312,687,673股减少至312,619,673股，库藏股数量增加至68,000股。公司于2026年6月18日通过本次股份购回授权，截至公告发布日，尚有31,268,767股的回购额度可供使用。\n公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由公司董事长兼首席执行官吴永谦签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B回购68,000股股份，总额约65.27万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117119869","title":"异动解读｜药捷安康-B盘中下跌8.13%，报9.83港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117119869","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117119869?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:36","pubTimestamp":1784255796,"startTime":"0","endTime":"0","summary":"7月17日，药捷安康-B盘中下跌8.13%，报9.83港元/股，成交额5932.94万港元。药捷安康-B所在的生物科技行业中，个股普遍承压，康方生物跌11.15%，三生制药跌11.17%，信达生物跌4.94%，科伦博泰生物跌5.49%，百济神州跌2.62%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147740288","title":"药捷安康-B（02617）获批开展TT-00973联合伏美替尼治疗EGFR突变NSCLC的中国II期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=1147740288","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147740288?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:21","pubTimestamp":1783693319,"startTime":"0","endTime":"0","summary":"药捷安康-B7月10日公告称，其产品TT-00973片联合甲磺酸伏美替尼用于治疗EGFR敏感突变局部晚期或转移性非小细胞肺癌的II期临床试验已获国家药品监督管理局批准。\\n\\n据公告，该试验为多中心、开放标签的II期研究，旨在评估TT-00973片联合甲磺酸伏美替尼在上述患者中的安全性与有效性。截至2025年12月31日，公司已完成TT-00973的I期临床试验，结果显示耐受性良好，并在部分实体瘤患者中观察到临床疗效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177708582","title":"药捷安康-B：国家药监局于2026年7月10日批准TT-973联合甲磺酸福莫替尼开展II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1177708582","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177708582?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:19","pubTimestamp":1783693176,"startTime":"0","endTime":"0","summary":"药捷安康（南京）科技有限公司宣布，其产品TT-973联合甲磺酸福莫替尼的II期临床试验申请，已于2026年7月10日获得中国国家药品监督管理局的批准。\n此项批准标志着该联合疗法的临床开发进入新阶段，即将在患者中进一步评估其安全性与有效性。II期试验旨在探索该方案在特定适应症中的治疗潜力，为后续研究奠定关键基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121234706","title":"异动解读｜药捷安康-B盘中上涨8.18%，核心产品III期临床完成入组叠加生物科技板块集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1121234706","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121234706?lang=zh_cn&edition=full","pubTime":"2026-07-10 11:11","pubTimestamp":1783653090,"startTime":"0","endTime":"0","summary":"7月10日，药捷安康-B盘中上涨8.18%，报11.11港元，成交额1.42亿港元。消息面上，公司7月1日公告核心产品替恩戈替尼单药治疗晚期胆管癌患者的全球多中心注册性III期临床试验已完成计划受试者入组，覆盖美国、欧洲及亚洲100多个临床中心。替恩戈替尼是全球首个且唯一针对FGFR抑制剂耐药胆管癌进入NDA阶段的研究药物，已获FDA孤儿药认证及快速通道资格。同日，公司另一产品TT-01488片联合抗CD20单抗治疗套细胞淋巴瘤的II期临床试验亦获国家药监局批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198637861","title":"异动解读｜药捷安康-B盘中上涨6.19%，生物科技板块集体走强叠加近期多项临床进展催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1198637861","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198637861?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:30","pubTimestamp":1783305010,"startTime":"0","endTime":"0","summary":"7月6日，药捷安康-B盘中上涨6.19%，报12.52港元，成交额1.23亿港元。此外，公司6月28日宣布拟回购最多1亿元H股，提振市场信心。板块层面，生物科技股今日集体走强，信达生物涨7.29%、科伦博泰生物涨6.21%、荣昌生物涨6.21%，行业情绪共振推动个股反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108635907","title":"药捷安康-B公布6月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1108635907","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108635907?lang=zh_cn&edition=full","pubTime":"2026-07-03 19:26","pubTimestamp":1783078018,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年7月3日发布2026年6月股份变动月报表，报告期为2026年6月。公司现有普通股按面值人民币1元划分为H股和非上市股份两类，期末法定（注册）股本合计407,918,633股，与上月底持平。公司未披露任何股份期权或股权激励计划在月度内发生变动。截至6月底，药捷安康-B总股本维持407,918,633股不变。公司确认在报告期内的证券发行及库藏股买卖行为均符合香港联交所《上市规则》及相关法律规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136444973","title":"异动解读｜药捷安康-B盘中上涨6.93%，核心产品替恩戈替尼III期临床完成入组叠加新管线获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1136444973","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136444973?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:24","pubTimestamp":1782959095,"startTime":"0","endTime":"0","summary":"7月2日，药捷安康-B盘中上涨6.93%，报12.29港元，成交额3.16亿港元。消息面上，公司7月1日接连发布两则研发进展公告：一是核心产品替恩戈替尼单药治疗晚期胆管癌患者的全球多中心注册性III期临床试验已完成入组，标志着该品种向注册上市迈出关键一步；二是公司产品TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的II期临床试验获国家药监局批准开展，进一步拓宽血液肿瘤管线布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648510186","title":"药捷安康-B(02617.HK)：替恩戈替尼单药治疗晚期胆管癌患者的全球多中心注册性III期临床试验完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2648510186","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648510186?lang=zh_cn&edition=full","pubTime":"2026-07-01 19:43","pubTimestamp":1782906234,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648451055","title":"药捷安康-B(02617)：TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的中国II 期临床试验获批开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2648451055","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648451055?lang=zh_cn&edition=full","pubTime":"2026-07-01 19:36","pubTimestamp":1782905809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，公司产品TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的II期临床试验，已于2026年7月1日获国家药品监督管理局批准。本试验为一项评价TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的多中心、开放标签、剂量探索和扩展的II期研究。多项临床证实BTK抑制剂联合抗CD20单抗可提升套细胞淋巴瘤一线治疗疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1732799900.SGD","LU0070217475.USD","LU1732800096.USD","LU2089279066.USD","LU2394011477.USD","SG9999002224.SGD","LU1718418525.SGD","02617","01488","LU0912757837.SGD","BK4588","IE0004086264.USD","BK1161","LU0154245756.USD","SG9999002232.USD","LU2211814178.USD","IE00BZ1G4Q59.USD","LU2211817866.USD","LU2552382132.HKD","LU2764262908.HKD","LU0323240290.USD","IE00BKVL7J92.USD","BK4533","LU2229751404.USD","LU2279689827.SGD","LU2463526074.USD","IE0004091025.USD","IE00B2PGVK34.USD","LU0210533765.USD","LU2552382058.USD","IE00BGHQF417.EUR","LU2764263039.SGD","LU2133065610.SGD","LU2347655073.USD","TT","LU0726765562.USD","LU0795875086.SGD","BK4585","BK4504","LU0323239441.USD","BK1233","LU2347655156.SGD","LU0154245673.USD","LU0266013472.USD","LU2720916845.USD","LU2552382215.SGD","LU0795875169.SGD","IE00B3CCJ633.GBP","BK4086","LU0238689110.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148791975","title":"异动解读｜药捷安康-B盘中下跌8.18%，回购计划提振效果消退解禁抛压延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1148791975","media":"行情直击","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148791975?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:00","pubTimestamp":1782788410,"startTime":"0","endTime":"0","summary":"6月30日，药捷安康-B盘中下跌8.18%，报11.68港元，成交额2.04亿港元。消息面上，公司于6月28日宣布最高1亿元人民币H股回购计划，6月29日股价曾大涨近20%，但回购利好提振效果迅速消退。此前6月23日，公司上市满一年迎来第二阶段解禁，约3.82亿股限售股解禁后遭大股东集中抛售，股价两日累计暴跌超60%，总市值从逾百亿港元缩水至不足50亿港元。当前1亿元回购规模相对解禁抛压体量有限，市场信心修复仍需时间。生物科技板块今日整体承压，康方生物跌4.31%、百济神州跌3.15%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183694473","title":"异动解读｜药捷安康-B盘中上涨19.89%，公司宣布最高1亿元H股回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1183694473","media":"行情直击","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183694473?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:05","pubTimestamp":1782698744,"startTime":"0","endTime":"0","summary":"6月29日，药捷安康-B盘中上涨19.89%，报10.9港元，成交额1.86亿港元。消息面上，公司于6月28日发布公告，董事会宣布根据股东周年大会批准的回购授权，计划在公开市场上回购公司H股，回购总金额最高为1亿元人民币或其等值港元。此次回购计划向市场释放积极信号，提振投资者信心。此外，公司核心产品替恩戈替尼的III期胆管癌临床已完成首例给药，前列腺癌II期获批开展，研发管线持续推进。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647134445","title":"港股异动 | 药捷安康-B(02617.HK)涨超10% 有意斥最高1亿元进行股份购回","url":"https://stock-news.laohu8.com/highlight/detail?id=2647134445","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647134445?lang=zh_cn&edition=full","pubTime":"2026-06-29 09:33","pubTimestamp":1782696797,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646312929","title":"药捷安康-B拟回购最多1亿元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646312929","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646312929?lang=zh_cn&edition=full","pubTime":"2026-06-28 18:42","pubTimestamp":1782643320,"startTime":"0","endTime":"0","summary":"6月28日，药捷安康-B（02617）发布公告，董事会宣布根据股东于2026年6月18日举行的股东周年大会批准的回购授权，计划在公开市场上回购公司H股，回购总金额最高为1亿元或其等值港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606283785588024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646332831","title":"港股异动 | 药捷安康-B(02617.HK)再跌超3% 市值较高点蒸发超98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646332831","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646332831?lang=zh_cn&edition=full","pubTime":"2026-06-26 14:26","pubTimestamp":1782455167,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":0.0461},{"period":"1month","weight":-0.6233},{"period":"3month","weight":-0.8234},{"period":"6month","weight":-0.875},{"period":"1year","weight":-0.6648},{"period":"ytd","weight":-0.9072}],"compareEarnings":[{"period":"1week","weight":0.0325},{"period":"1month","weight":0.0505},{"period":"3month","weight":-0.0394},{"period":"6month","weight":-0.0562},{"period":"1year","weight":0.0055},{"period":"ytd","weight":-0.0194}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药捷安康（南京）科技股份有限公司是一家从事生物制药的中国公司，主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。该公司的核心产品Tinengotinib是一种处于注册临床阶段的内部发现和开发的MTK抑制剂，适用于某些复发或难治的耐药实体瘤。该公司的肿瘤产品线包括TT-00973（针对 AXL）、TT-01488（用于血液系统恶性肿瘤）、TT-01688（用于炎症性疾病）和 TT-00920（用于慢性心力衰竭）。这些产品能够对多种癌症类型（包括前列腺癌、肝癌、乳腺癌和BTC）产生疗效。它还可用于治疗肝细胞癌、乳腺癌、胆道癌和Pan-FGFR实体瘤。","exchange":"SEHK","name":"药捷安康-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药捷安康-B,02617,药捷安康-B股票,药捷安康-B股票老虎,药捷安康-B股票老虎国际,药捷安康-B行情,药捷安康-B股票行情,药捷安康-B股价,药捷安康-B股市,药捷安康-B股票价格,药捷安康-B股票交易,药捷安康-B股票购买,药捷安康-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}